Immunohistochemical Study of Androgen Receptor Expression in Estrogen Receptor-Negative Invasive Breast Carcinoma and its Relation with Clinicopathologic Factors

Shereen E. Abdelaal; Samia M. Gabal; Amina A. Gamal el Din; Hala N. Hosni; Hafiza A. Sharaf

doi:10.3889/oamjms.2020.5321

Authors

Shereen E. Abdelaal Department of Pathology, National Research Centre, Giza, Egypt
Samia M. Gabal Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Amina A. Gamal el Din Department of Pathology, National Research Centre, Giza, Egypt
Hala N. Hosni Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Hafiza A. Sharaf Department of Pathology, National Research Centre, Giza, Egypt

DOI:

https://doi.org/10.3889/oamjms.2020.5321

Keywords:

Androgen receptor, Estrogen receptor-negative, Breast carcinoma, Immunohistochemistry

Abstract

BACKGROUND: Estrogen receptor (ER)-negative breast carcinomas lack the expression of ER and they have no targeted hormone therapies. The androgen receptor (AR) is a newly emerge biomarker. Detecting AR in these tumors may provide a target for future therapies.

AIM: The aim of the study is to examine the immunohistochemical expression profiles of AR protein in ER-negative invasive breast carcinomas and to assess the relation between AR expression and the clinicopathologic factors such as age, tumor size, tumor grade, tumor type, immunohistochemical type, lymph node status, and Ki67 expression.

METHODS: Sixty paraffin blocks of ER-negative invasive breast carcinoma cases were stained immunohistochemically by AR. Positive expression was defined as ≥1% nuclear staining.

RESULTS: AR positivity was detected in 55% of the studied cases. The positive cases were scored by H-score with a median=117, and a range of 3–285 and by Allred score with a median=7, and a range of 3-8. AR is expressed in 60.9% of triple-negative breast carcinoma cases. AR expression was higher in older age, and there were significant positive correlations between the degree of AR expression (AR%, AR intensity, and H-score) and age (p=0.050, 0.007, 0.033, respectively). There was non-significant negative correlation between Ki67% and the degree of AR expression (AR%, AR intensity, H-score, and Allred score). Regarding different histological types, tumor grade, tumor size, lymph node status, and immunohistochemical types, there was no significant difference between AR positive and AR negative cases.

CONCLUSION: AR is frequently expressed in ER-negative invasive breast carcinoma; especially in older age, and in a large number of triple-negative subtypes. This may give chance to benefit from future AR target therapy. We recommend further research work on AR expression in the special histologic subtypes of ER-negative breast carcinoma and in the triple negative group.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Christopoulos PF, Vlachogiannis NI, Vogkou CT, Koutsilieris M. The role of the androgen receptor signaling in breast malignancies. Anticancer Res. 2017;37(12):6533-40. PMid:29187427

Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:e437971. https://doi.org/10.1155/2014/437971

Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: A meta-analysis. Biomed Res Int. 2015;2015:357485. https://doi.org/10.1155/2015/357485 PMid:25695063

Munirah MA, Siti-Aishah MA, Reena MZ, Sharifah NA, Rohaizak M, Norlia A, et al. Identification of different subtypes of breast cancer using tissue microarray. Rom J Morphol Embryol. 2011;52(2):669-77. PMid:21655659

Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20(1):119-31. https://doi. org/10.1016/j.ccr.2011.05.026 PMid:21741601

Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res. 2012;2(4):434-45. PMid:22860233

Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205-12. https://doi.org/10.1038/modpathol.2009.159 PMid:19898421

Vellaisamy G, Tirumalae R, Inchara YK. Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status. J Cancer Res Ther. 2019;15(5):989-93. https:// doi.org/10.4103/jcrt.jcrt_572_17 PMid:31603099

Damjanov I, Fan F. Cancer Grading Manual. 2nd ed. Berlin: Springer-Verlag; 2013.

World Health Organization Classification of Tumours Editorial Board. Who Classification of Tumours: Breast Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2019. p. 82-159.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017.

Allison KH, Hammond ME, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346-66. https://doi.org/10.1200/ jco.19.02309

Brouckaert O, Paridaens R, Floris G, Rakha E, Osborne K, Neven P. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013;24(1):47-53. https://doi.org/10.1093/annonc/mds238 PMid:22847811

Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: Recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2011;103(22):1656-64. https://doi.org/10.1093/jnci/djr393 PMid:21960707

Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/ PR-negative breast cancers. Virchows Arch. 2010;457(4):467- 76. https://doi.org/10.1093/jnci/djr393 PMid:20809337

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488-92. PMid:19887463

Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867- 74. https://doi.org/10.1093/jnci/djr393 PMid:21325075

Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the nurses’ health study. Mod Pathol. 2011;24(7):924-31. https://doi.org/10.1038/ modpathol.2011.54 PMid:21552212

Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22:1288-94. https://doi. org/10.1093/annonc/mdq586 PMid:21109569

Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, et al. Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl). 2012;6:1-8. https://doi.org/10.4137/bcbcr.s8323 PMid:22259247

Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, et al. A majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer. 2014;5(2):156-65. https://doi.org/10.7150/jca.7668 PMid:24563670

Sutton LM, Cao D, Sarode V, Molberg KH, Torgbe K, Haley B, et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol. 2012;138(4):511-6. https://doi.org/10.1309/ajcp8avf8fdptzlh PMid:23010705

Mrklić I, Pogorelić Z, Capkun V, Tomić S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2013;115(4):344-8. https://doi.org/10.1016/j.acthis.2012.09.006 PMid:23031358

Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: Is routine AR assessment justified? Am J Cancer Res. 2014;4(4):353-68. PMid:25057438

Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol. 2012;138(6):796-802. https://doi. org/10.1309/ajcp6dkrnd5ckvdd PMid:23161712

Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M, et al. Androgen receptor expression in early triple-negative breast cancer: Clinical significance and prognostic associations. Cancers (Basel). 2014;6(3):1351-62. https://doi. org/10.3390/cancers6031351 PMid:24978437

McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. Ann Surg Oncol. 2014;21(2):361-7. https://doi.org/10.1245/ s10434-013-3260-7 PMid:24046116